Differential expression of genes influencing mitotic processes in cord blood mononuclear cells after a pre-conceptional micronutrient-based randomized controlled trial: Pune Rural Intervention in Young Adolescents (PRIYA)

Satyajeet P. Khare[1,2#], Ayush Madhok[1#], Indumathi Patta[1], Krishna K. Sukla[3], Vipul V. Wagh[2], Pooja S. Kunte[3], Deepa Raut[3], Dattatrey Bhat[3], Kalyanaraman Kumaran[4], Caroline Fall[4], Utpal Tatu[5], Giriraj R Chandak[6], Chittaranjan Yajnik[3]*, Sanjeev Galande[1, 7]*

1. Centre of Excellence in Epigenetics, Department of Biology, Indian Institute of Science Education and Research (IISER), Pune, Pashan, Pune, Maharashtra 411008, India
2. Symbiosis School of Biological Sciences (SSBS), Symbiosis International (Deemed University), Lavale, Pune, Maharashtra, 412115, India
3. King Edward Memorial Hospital Research Centre, Pune, Maharashtra, 411022, India
4. Medical Research Council Lifecourse Epidemiology Unit, Southampton, UK
5. Indian Institute of Science (IISC), Bangalore, India
6. Genomic Research on Complex diseases (GRC-group), CSIR-Centre for Cellular and Molecular Biology, Hyderabad, India
7. Department of Life Sciences, Shiv Nadar University, Gautam Buddha Nagar, Uttar Pradesh, 201314, India.

[#] These authors contributed equally

*** For correspondence**:

csyajnik@gmail.com

sanjeev@iiserpune.ac.in

Keywords: Vitamin B12 and micronutrients, randomized controlled trial, cord blood mononuclear cells, gene expression profiling, cell cycle, mitotic processes.

Abstract:

In The Pune Maternal Nutrition Study, vitamin B12 deficiency was seen in 65% of pregnant women, folate deficiency was rare. Low maternal vitamin B12 and high folate concentrations during pregnancy predicted higher adiposity and insulin resistance in the offspring. These findings guided a nested randomized controlled trial 'Pune Rural Intervention in Young Adolescents (PRIYA)'. The interventions included: 1) vitamin B12+multi-micronutrients and proteins (B12+MMN), 2) vitamin B12 (B12 alone), and 3) placebo. Intervention improved maternal and offspring pre-conceptional and in-pregnancy micronutrient nutrition, though this did not reflect in neonatal anthropometry. Gene expression analysis in cord blood mononuclear cells in 88 pregnancies revealed 75 differentially expressed genes between the B12+MMN and placebo groups. The enriched biological processes included: chromosome segregation, nuclear division, and G2/M phase transition; however, expression of proliferation markers did not differ. Enriched pathways included: Mitotic spindle checkpoint and DNA damage response. Enriched human phenotypes included: Sloping forehead and Decreased head circumference. *FBP2* and *CDCA2* genes were differentially expressed between the B12 alone and placebo groups. The latter, involved in chromosome segregation was under-expressed in both intervention groups. Based on the role of B-complex vitamins in synthesis of nucleotides and S-Adenosyl Methionine (SAM), and nuclear influences of vitamins A and D, we propose that the multi-micronutrient intervention epigenetically affected cell cycle dynamics. Vitamin B12 alone was not sufficient. Follow up studies will reveal if our intervention and the altered biological processes influence long-term phenotype in the offspring including adiposity, diabetes related traits, and neurocognitive performance.

Introduction:

The Developmental Origins of Health and Disease (DOHaD) paradigm proposes that the environment during crucial stages of development modifies gene expression through various epigenetic changes which permanently affect the structure and function of the developing organism (Heindel and Vandenberg, 2015). This phenomenon is also called 'fetal programming' (Lucas et al., 1999). This paradigm was derived from Prof. David Barker's demonstration that low birth weight (indicative of poor fetal nutrition) was a risk factor for future diabetes and cardiovascular disease (Barker et al., 1989). This suggested a role for improving fetal nutrition to prevent common non-communicable diseases.

Fetal programming is an epigenetic phenomenon and depends on chemical modifications of DNA and histones or action of non-coding RNAs, all of which influence gene expression (transcription and translation) (Gluckman et al., 2008). DNA methylation is the most studied, and is influenced by dietary nutrients which provide or generate methyl groups for cellular metabolism (Switzeny et al., 2012; Kok et al., 2015). These nutrients include vitamins B12, B2, B6, folate, choline, betaine, and proteins (Zeisel, 2017). Vitamins A and D are also known to influence gene expression through their interaction with the nuclear receptors (Berry et al., 2011; Pasing et al., 2017). Deficiency of these nutrients in the diet of a pregnant mother manifests in adverse effects on the fetus, including developmental defects (neural tube defects, midline congenital defects etc.), growth abnormalities (growth restriction) (Gernand et al., 2016), and are also associated with an increased risk of non-communicable diseases in later life (Deshmukh et al., 2013; Pandit et al., 2021).

The Pune Maternal Nutrition Study (PMNS) is a community based pre-conceptional birth cohort started in 1993 after Prof. Barker's theory (Rao et al., 2003). It was set up in six villages near Pune to study maternal nutritional determinants of fetal growth and to study life-course evolution of the risk of diabetes and adiposity in the offspring. We found that two thirds of the pregnant mothers had low vitamin B12 status but folate status was adequate in the majority (Yajnik et al., 2007). Low maternal B12 status coupled with normal to high folate status was associated with increased risk of diabesity (adiposity and insulin resistance) in the offspring during childhood (Yajnik et al., 2007) and young adulthood (Wagh et al., 2020). Vitamin D deficiency in the mothers was also associated with increased adiposity in the children. These findings prompted us to set up the Pune Rural Intervention in Young Adolescents (PRIYA) trial (ISRCTN 32921044 and CTRI 2012/12/003212) (Kumaran et al., 2017). The trial provided vitamin B12 and other micronutrients (B-complex vitamins, vitamins A, D, and E, and trace elements), along with milk proteins to the adolescent women in the PMNS cohort with an aim to reduce the risk of diabesity in their offspring in later life. In the short term, we will investigate effects on birth size and changes in DNA methylome, transcriptome, proteome, and metabolome in the cord blood of the newborn.

Even though the success of the long-term aim will be revealed only in future, the short-term aims to measure changes in fetal growth and multi-omic changes in the cord blood are currently possible. The purpose of this paper is to describe the exciting preliminary results on transcriptomic changes in the cord blood (alterations in cell cycle dynamics) which may influence the long-term outcomes in the PRIYA trial as mentioned above.

Materials and Methods:

The PRIYA trial

The rationale and methods of the PRIYA trial are described previously (Kumaran et al., 2017).

Participants: PRIYA is a randomized, double blind, placebo-controlled trial in adolescent participants of the PMNS (Figure 1). In short, 690 adolescent participants (average age 16.3 years, 362 boys, 328 girls) were screened for B12 levels and hemoglobin concentrations to exclude those with severe vitamin B12 deficiency (plasma vitamin B12 concentration <100 pmol/L) or severe anaemia (blood hemoglobin concentration <70 gm/L). This was to fulfil ethical imperatives of a placebo controlled trial. Those with chronic medical conditions were also excluded.

Ethics permissions and trial registration

The PRIYA trial was approved by the KEM Hospital Research Centre Ethics committee and monitored by a Data Safety Monitoring Board (DSMB) and a Scientific Advisory Committee (SAC). Informed consent was signed by parents all participants, and an informed assent was signed by participants below 18 years of age. After attaining 18 years of age, all participants signed their own informed consent.

The trial was registered with the CTRI (2012/12/003212) and ISRCTN (32921044).

Intervention and Comparator: Eligible participants were randomised into 3 intervention groups: 1) vitamin B12 (2 μg/day) along with multi-micronutrients as per United Nations International Multiple Micronutrient Antenatal Preparation (UNIMMAP) (World Health Organization, 1999), excluding folic

acid and conforming to local regulatory requirements (Supplementary Table 1), 2) Placebo, 3) vitamin B12 (2 μg/day) alone. The multi-micronutrient group also received 20 gm of milk powder every day and all 3 groups received iron and folic acid as per Government of India approved dosage (60 mg elemental iron + 500 μg folic acid once a week before pregnancy and one tablet daily for at least 100 days during pregnancy). Every month bottles were distributed by local field staff who were in regular touch with the participants. Bottles were returned each month for counting the unused capsules, this information was used for calculating compliance. The trial intervention was continued until delivery of the first live child.

Outcomes: A blood sample was obtained for measurement of circulating micronutrients 6-12 months after the intervention was started. Marriages were recorded, and the pregnancies were diagnosed by a urine pregnancy test when pregnancy was suspected. At 28-weeks' gestation, an obstetric consultation as well as blood tests were performed (hemogram, micronutrients and an oral glucose tolerance test). Local medical practitioners also treated the pregnant women as required. The field staff visited and monitored the pregnant women regularly and helped transfer them for delivery at the King Edward Memorial (KEM) Hospital, Pune.

Trained research staff attended the deliveries and collected cord blood samples as per a standardised protocol. Details of the delivery and baby's anthropometric measurements were also recorded. A cord blood aliquot was transferred to PAXgene tubes (BD, USA) and stored at -80°C till further processing.

Blood measurements

Plasma vitamin B12, B6, holo-TC ('active' B12), folate, and total homocysteine were measured at baseline (before starting the intervention), 6-12 months after starting intervention, at 28 weeks gestation, at delivery, and in the cord blood. Vitamin B2 was also measured at these time-points except at the baseline. Supplementary Table 2 describes the laboratory methods used for these measurements.

Statistical methods for clinical characteristics:

The data for maternal and neonatal clinical characteristics is represented as median (IQR). The significance of difference between intervention and placebo groups was tested by Mann-Whitney test for two group comparison, and by Kruskal-Wallis test for multi-group comparison.

Isolation of cord blood mononuclear cells

Mononuclear cells from the cord blood were extracted after depleting RBCs from whole blood. In brief, batches of frozen blood samples were thawed and diluted with one volume of phosphate buffer saline supplemented with EDTA (2mM). One volume of RBC lysis buffer (Biolegend # 420301) was added to the diluted samples and incubated for 5 minutes at RT. The tubes were centrifuged at 350 x g for 15 min at 4°C and the pellets were processed for RNA isolation.

RNA isolation, sequencing and data analysis

Cord blood mononuclear cells were subjected to RNA isolation using TriZol reagent (Invitrogen). Quantitation of RNA was performed on Qubit 4 Fluorometer (Thermo Scientific #Q33238) using RNA

HS Kit (Thermo Scientific #Q32852). Libraries were prepared according to the manufacturer's protocol (Illumina). Briefly, each sample was run on 2100 Bioanalyzer (Agilent #G2939BA) to check its integrity. About 500 ng of total RNA from each sample was used to make libraries using TruSeq Stranded mRNA Sample Prep Kit (Illumina #20020594). After final quantification and pooling, the libraries were run on Illumina HiSeqX platform, with 150 nucleotides long paired end reads as the output.

The quality of sequencing was assessed using FastQC (v0.11.8). The raw sequence reads were aligned to the human genome (hg38, Gencode) (Frankish et al., 2019) using HiSAT2 (Kim et al., 2019). The resulting BAM files were used to generate a count matrix using featureCounts for known genes (Liao et al., 2014). Samples with reads that aligned poorly (Q1-IQR*1.5) were excluded from the downstream analysis. Low expression genes (less than 20 counts in total in all samples) were not included for the differential expression analysis. Gene expression levels were normalized by internal normalization method by calculating geometric mean in DESEq2 (Love et al., 2014). Normalized expression values were regularized log transformed for PCA plots. Differential expression analysis was performed between the placebo group and the intervention groups by two-group comparison using the default Wald test in DESeq2. Maternal age at the start of intervention, duration of intervention, sex of the child, and cord blood monocyte, granulocyte, and lymphocyte counts were used as covariates. Absolute values of these covariates were converted to categorical variables around the median. Since the samples were processed in batches, the batch numbers were also used as a covariate. FDR adjusted P-value cut-off of 0.05 and base mean value cut-offs of 1 were used for identification of differentially expressed genes. Significantly differentially expressed genes were subjected to gene enrichment analysis using clusterProfiler (v3.14.3) (Yu et al., 2012) and gProfiler (version:e105_eg52_p16_e84549f) (Raudvere et al., 2019). To understand the gene-networking, the differentially expressed genes (DEGs), were subjected to gene network analysis using STRING (Szklarczyk et al., 2019).

Results:

Trial progress and clinical findings:

Six hundred and ninety adolescent participants in the PMNS were screened for inclusion in the PRIYA trial in the year 2012 (Figure 1). A total of 133 were excluded and 557 (266 females, 291 males, average age 16.3 years (min = 15.4, max= 17.5)) were randomized into 3 groups. The intervention was started in September 2012. This paper refers to outcomes only in female participants. A total of 182 females in the trial married, 166 became pregnant and 149 delivered in the study. Cord blood samples were available on 138 for gene expression analysis. This paper reports transcriptome measurements on the first 88 cord blood samples (40 girls, 48 boys); these pregnancies were comparable to the 50 who were not included in this study [with respect to maternal age, body mass index (BMI), socio-economic status, and hemoglobin concentrations at 28 weeks gestation, $p > 0.05$].

During pregnancy, the mothers were on average 21 years old and weighed 53.0 kgs with a BMI of 22.0 kg/m^2 (Table 1). The first delivery was in November 2014 and the last delivery was in February, 2020. The duration of intervention was on an average of 54 months (min = 24, max = 83). Three mothers delivered pre-term, and 23 were delivered by caesarean section. The average birth weight of babies was 2.8 kg, 14 were low birth weight (i.e., <2.5 kg) (Table 2). There was no significant difference in the birth weight, length, skin fold thicknesses in the 3 groups, however, ponderal index

was higher in the B12+MMN group compared to the other two groups. The pregnancy outcomes (pre-term deliveries, caesarean sections, and common adverse events) were similar in the three intervention groups.

At baseline, as a group plasma vitamin B12 concentrations were low and 47.7% were B12 deficient (<150 pmol/L), only 1% were folate deficient (<7 nmol/L). Plasma homocysteine concentrations were high, 91% had hyperhomocysteinemia (>15 μmol/L). There was no significant difference in plasma vitamin B12, folate and homocysteine concentrations in the 3 intervention groups.

Figure 2 shows serial concentrations of vitamin B12, holo-TC , folate and total homocysteine during the trial. It can be seen that, in women in the two vitamin B12 supplemented groups there was a sizeable rise in vitamin B12 and holo-TC concentrations compared to the placebo group, and a fall in total homocysteine concentrations within a few months. The levels of all these metabolites fell during pregnancy (as expected), but vitamin B12 and holo-TC remained higher in the two intervention groups. Vitamin B2 and B6 were the highest in the B12+MMN group after intervention (Table 1). Maternal hemoglobin concentrations and other hematological parameters were similar in the three groups. The measured compliance was similar in the three intervention groups.

Cord blood concentrations of vitamin B12, holo-TC, and folate were higher than the maternal concentrations. Although vitamin B12 and holo-TC were higher in the B12 supplemented groups, the difference from the placebo group was not significant. (Figure 2, Table 1). Cord blood hemoglobin concentration and red cell count were the highest in the group supplemented with B12 alone. The total leucocyte count and individual counts of granulocytes, lymphocytes, monocytes, and platelets were similar in the 3 groups.

RNA sequencing and differential gene expression analysis:

Mononuclear cells from 88 cord blood samples were subjected to RNA sequencing. Each sample generated approximately 50 million reads. Out of the 88 samples, 9 samples showed poor alignment against the reference genome and were not considered for the downstream analysis. Our final analysis was therefore, on 79 samples. All samples showed comparable assignment to genes for generation of count matrix. The count matrix was used for differential expression analysis.

Samples showed clear separation based on the sex of the child on principal component analysis (PCA), however, no separation was observed based on any other covariate or the intervention (data not shown). Differential expression analysis between the B12+MMN group and placebo resulted in identification of 75 differentially expressed genes (DEGs) (Figure 3A, Table 3, and Supplementary Table 3).

We used clusterProfiler and gProfiler to identify the top biological processes, pathways, and phenotypes affected by the DEGs (Figure 3B and Supplementary Figure 1). Participants supplemented with B12+MMN showed lower expression of genes associated with mitotic processes such as chromosome segregation, nuclear division, and G2/M phase transition as compared to the placebo group. To understand the gene-networking of the 75 DEGs, we performed analysis using STRING. Of the 75 DEGs, 71 formed a network with 12 showing association with the biological process 'negative regulation of cell cycle' (Figure 3C). Cell proliferation markers such as Cyclin D1 *(CCND1), PCNA,* and Ki-67 (*MKI67*) did not show significant differences in gene expression; however,

pathway analysis identified enrichment of Cell Cycle Checkpoints and DNA damage response pathways. Enrichment of human phenotype terms Sloping forehead and Decreased head circumference was also observed. Two differentially expressed genes were observed between placebo and the B12 alone group, one of which *CDCA2 (Cell Division Cycle Associated 2)* was common to the B12+MMN group (Figure 3D). The 75 genes differentially expressed between B12+MMN and placebo also showed similar trend in expression in the B12 alone group but did not reach statistical significance (Supplementary Table 3). No significantly differentially expressed genes were observed between the two active intervention groups.

Discussion:

In this communication, we report the effect of a maternal pre-conceptional and pregnancy intervention with vit B12 and multi-micronutrients on the offspring's cord blood transcriptome in the PRIYA trial. Vitamin B12+MMN intervention resulted in differential expression of 75 genes predominantly influencing mitotic processes such as chromosomal segregation, nuclear division, G2/M phase transition, etc. when compared to placebo. Vitamin B12 alone did not significantly influence the transcriptome except for *CDCA2* and *FBP2* genes; though, the pattern of gene expression was similar in the two intervention groups. To our knowledge, this is the first report of changes in cord blood transcriptome after a maternal nutritional intervention started from before conception. The majority of similar studies have reported changes in DNA methylation but not gene expression in cord blood in response to maternal vitamin B12 supplementation (Fryer et al., 2011; Cooper et al., 2012; Khulan et al., 2012; McKay et al., 2012; McCullough et al., 2016) and folate supplementation (Hoyo et al., 2011; Qian et al., 2016; Pauwels et al., 2017; Tserga et al., 2017; Caffrey et al., 2018; Irwin et al., 2019). A more elaborate systematic review has reported the effect of multi-micronutrients other than vitamin B12 and folate only on DNA methylation in the offspring (Andraos et al., 2018; James et al., 2018).

Nutritional deficiencies are common in the population of villages we studied. Our intervention was prompted by our findings in earlier studies in the same cohort which showed a substantial vitamin B12 deficiency in the participants and their parents, and an association between maternal low vitamin B12-high folate status and risk of diabesity in the offspring (Yajnik et al., 2007). These villages are drought prone and residents have poor socio-economic status which would contribute to multiple micronutrient deficiencies, and poor growth and development in babies. Our intervention showed a demonstrable increase in maternal levels of vitamins B12, holo-TC, B2, and B6 in the multi-micronutrient group and of vitamin B12 and holo-TC in the B12 alone group, within a few months of starting the intervention and persisting in the pregnancy. There was a significant fall in plasma total homocysteine levels, suggesting a favorable one-carbon metabolism status and methylation potential of the cell. Given the additional micronutrient contents of the capsules, we would also expect better nutrition of vitamins A, D, and E and other micronutrients (Zn etc.) in the MMN group. This would translate into better nutrition of the ovum before conception and of the conceptus throughout pregnancy. Despite significant differences in the levels of micronutrients in maternal circulation, a relative lack of differences in some of these micronutrients in the cord blood may have been contributed by alterations in placental transport, binding to carrier proteins, and differential utilisation by the baby (Whitfield et al., 2006; Lager and Powell, 2012). An inspection of the one-carbon (1-C) metabolic cycle (Figure 4) and its regulation by B-complex vitamins suggests that babies of mothers who received vitamin B12+MMN would have a more comprehensive effect on nucleotide

synthesis and therefore on DNA and RNA metabolism compared to those who received vitamin B12 alone. Reasons for higher hemoglobin and red blood cell counts in the vitamin B12 alone group are not apparent but could be related to higher levels of vitamin B12 and holo-TC in this group.

A detailed analysis of our results suggested that the differentially expressed gene in the vitamin B12+MMN group were associated with biological processes such as chromosome segregation, nuclear division, G2/M transition, etc. Of these 75 DEGs, 71 clustered in a network with 12 genes showing an association with negative regulation of cell cycle. These results remind us of the changes described in the bone marrow of patients with pernicious anaemia (a severe vitamin B12 deficiency condition which creates a functional folate deficiency and reduced methylation potential). The biochemical, cellular and morphological changes in this condition include: block in deoxyuridine to thymidine conversion leading to disturbed DNA synthesis and repair, prolongation of S-phase, maturation arrest and failure of cell division. Two studies investigated the effect of cobalamin (vitamin B12) deficiency on nerve cells in culture and found slower proliferation and accelerated differentiation of neuroblastoma cells (Battaglia-Hsu et al., 2009) and impaired DNA synthesis, prolonged G2/M phase transition leading to cell growth without cell division in human astrocytes (Rzepka et al., 2019).

We also investigated the expression of standard cell proliferation markers such as cyclin D1, Minichromosome Maintenance Complex Component 2 (*MCM2*), Proliferating Cell Nuclear Antigen (*PCNA*) and Ki-67 from the RNA-Seq data (Whitfield et al., 2006). None of these proliferation markers showed a significant change in expression in either intervention groups compared to the placebo group at the set threshold. However, various cell cycle checkpoint and DNA repair related genes showed higher expression in the Placebo group. We propose that deficiency of micronutrients in the placebo group results in a compensatory increase in the expression of genes involved in nucleic acid synthesis and cell division triggered by hypomethylation of the relevant genes. However, micronutrient deficiency compromises the supply of nucleotides for DNA synthesis and replication resulting in activation of cell cycle checkpoint. On this background, it appears that genes related to DNA synthesis and cell division were under-expressed in the B12+MMN group because the intervention led to better micronutrient status, nucleotide availability, and better methylation status which would promote methylation of the relevant genes. Indeed in a recent paper we reported that children supplemented with B12 and folic acid showed differential DNA methylation in the genes associated with G2/M checkpoint regulation (Yadav et al., 2018).

Our multi-micronutrient composition also included vitamins A and D, and zinc which are known to affect gene expression and cell proliferation in specific tissues (MacDonald, 2000; Blomhoff, 2004; Umar et al., 2018) over and above the effect of B-complex vitamins. We speculate that they could presumably contribute to some of our findings of gene expression differences including those on shape and growth of the skull.

Strengths and Limitations: A major strength of our intervention is that it was guided by earlier nutritional observations in the same cohort and that it was truly pre-conceptional (from adolescent age) and therefore, had the potential of influencing peri-conceptional epigenetic reprogramming. Use of 'physiological' doses of micronutrients was based on the successful results of a pilot trial (Deshmukh et al., 2010), and made it public health relevant. The limitations include that these preliminary results are on a relatively small number. These numbers will increase after results on the

remaining samples are available. The limited power could also have contributed to a lack of difference in the cord blood measurements of some of the vitamins and in body size measurements of the babies in the three groups. Another limitation is that our transcriptomic measurements are limited only to cord blood mononuclear cells which may not reflect changes in other tissues. Such invasive studies are difficult in humans for ethical reasons. Study of transcriptome provided us with an opportunity to investigate intermediate signatures of the epigenetic influences of our intervention. In subsequent papers we will report the results of cord blood methylome, proteome, and metabolome which may allow a better understanding of the full range of 'epigenetic' changes in response to micronutrient intervention.

Our results provide perhaps the first human evidence of maternal micronutrient intervention on transcriptome of cord blood mononuclear cells. The intervention affected vital processes like cell cycle regulation and mitotic division, and growth of head circumference. These gene expression changes are plausible mechanisms for influencing intrauterine programming of future health and disease. Follow up studies in children will provide an opportunity to investigate the association of these alterations with outcomes of body size and composition, metabolism, and neurocognitive function.

Data availability

The datasets generated for this study can be found in NCBI SRA: PRJNA756634.

Funding

The work was supported by research grants from Department of Biotechnology (DBT), Government of India (CEIB-BT/PR12629/MED/97/364/2016) and Indian Council of Medical Research (ICMR) – Medical Research Council (MRC), UK grant (No.58/1/8/ICMR-MRC/2009-NCD-II).

Acknowledgement

AM, IP, and VW thank CSIR-UGC, Government of India for research fellowships. SPK is also a beneficiary of a DST SERB SRG grant (SRG/2020/001414). The authors thank Drs Ameya Sathe, Ankitha Shetty for their help in processing cord blood samples, Saurabh Pradhan for help with RNA-seq, Neelam Memane and Rajashree Kamat for laboratory assays, Aboli Bhalerao and Madhura Deshmukh, MSWs and ANMs for their help in the PRIYA study, Mrs. Pallavi Yajnik and Rasika Ladkat for administrative help.

Author contributions

SPK and AM designed the experiments, performed the RNA-Seq analysis and wrote the manuscript. IP assisted in optimization of cell isolation and RNA preparation. KKS, VW, PSK helped in data analysis and drafting the manuscript. CSY and CF designed the PRIYA trial. KK contributed to running the trial. GC and UT contributed to the discussion and interpretations. DR and DB assisted in sample collection. SG designed the experiments. CSY and SG discussed and interpreted the results, supported the research, and wrote the manuscript. All authors read and approved the manuscript.

Conflict of interest

The authors have declared no competing interest.

References:

Andraos, S., de Seymour, J., O'Sullivan, J., and Kussmann, M. (2018). The Impact of Nutritional Interventions in Pregnant Women on DNA Methylation Patterns of the Offspring: A Systematic Review. *Mol. Nutr. Food Res.* 62. doi:10.1002/MNFR.201800034.

Barker, D. J., Winter, P. D., Osmond, C., Margetts, B., and Simmonds, S. J. (1989). Weight in infancy and death from ischaemic heart disease. *Lancet (London, England)* 2, 577–580. doi:10.1016/S0140-6736(89)90710-1.

Battaglia-Hsu, S., N, A., N, N., JM, A., E, J., CE, O.-B., et al. (2009). Vitamin B12 deficiency reduces proliferation and promotes differentiation of neuroblastoma cells and up-regulates PP2A, proNGF, and TACE. *Proc. Natl. Acad. Sci. U. S. A.* 106, 21930–21935. doi:10.1073/PNAS.0811794106.

Berry, D. C., Jin, H., Majumdar, A., and Noy, N. (2011). Signaling by vitamin A and retinol-binding protein regulates gene expression to inhibit insulin responses. *Proc. Natl. Acad. Sci. U. S. A.* 108, 4340–4345. doi:10.1073/PNAS.1011115108.

Blomhoff, H. K. (2004). Vitamin A regulates proliferation and apoptosis of human T- and B-cells. *Biochem. Soc. Trans.* 32, 982–984. doi:10.1042/BST0320982.

Caffrey, A., Irwin, R., McNulty, H., Strain, J., Lees-Murdock, D., McNulty, B., et al. (2018). Gene-specific DNA methylation in newborns in response to folic acid supplementation during the second and third trimesters of pregnancy: epigenetic analysis from a randomized controlled trial. *Am. J. Clin. Nutr.* 107, 566–575. doi:10.1093/AJCN/NQX069.

Cooper, W., Khulan, B., Owens, S., Elks, C., Seidel, V., Prentice, A. M., et al. (2012). DNA methylation profiling at imprinted loci after periconceptional micronutrient supplementation in humans: results of a pilot randomized controlled trial. *FASEB J.* 26, 1782–1790. doi:10.1096/FJ.11-192708.

Deshmukh, U. S., Joglekar, C. V., Lubree, H. G., Ramdas, L. V., Bhat, D. S., Naik, S. S., et al. (2010). Effect of physiological doses of oral vitamin B12 on plasma homocysteine: a randomized, placebo-controlled, double-blind trial in India. *Eur. J. Clin. Nutr.* 64, 495–502. doi:10.1038/EJCN.2010.15.

Deshmukh, U. S., Katre, P., and Yajnik, C. S. (2013). Influence of maternal vitamin B12 and folate on growth and insulin resistance in the offspring. *Nestle Nutr. Inst. Workshop Ser.* 74, 145–156. doi:10.1159/000348463.

Frankish, A., Diekhans, M., Ferreira, A. M., Johnson, R., Jungreis, I., Loveland, J., et al. (2019). GENCODE reference annotation for the human and mouse genomes. *Nucleic Acids Res.* 47, D766–D773. doi:10.1093/nar/gky955.

Fryer, A. A., Emes, R. D., Ismail, K. M., Haworth, K. E., Mein, C., Carroll, W. D., et al. (2011). Quantitative, high-resolution epigenetic profiling of CpG loci identifies associations with cord blood plasma homocysteine and birth weight in humans. *Epigenetics* 6, 86–94. doi:10.4161/EPI.6.1.13392.

Gernand, A. D., Schulze, K. J., Stewart, C. P., West, K. P., Jr, and Christian, P. (2016). Micronutrient deficiencies in pregnancy worldwide: health effects and prevention. *Nat. Rev. Endocrinol.* 12, 274. doi:10.1038/NRENDO.2016.37.

Gluckman, P. D., Hanson, M. A., Cooper, C., and Thornburg, K. L. (2008). Effect of in utero and early-

life conditions on adult health and disease. *N. Engl. J. Med.* 359, 61–73. doi:10.1056/NEJMRA0708473.

Heindel, J. J., and Vandenberg, L. N. (2015). Developmental Origins of Health and Disease: A Paradigm for Understanding Disease Etiology and Prevention. *Curr. Opin. Pediatr.* 27, 248. doi:10.1097/MOP.0000000000000191.

Hoyo, C., Murtha, A., Schildkraut, J., Jirtle, R., Demark-Wahnefried, W., Forman, M., et al. (2011). Methylation variation at IGF2 differentially methylated regions and maternal folic acid use before and during pregnancy. *Epigenetics* 6, 928–936. doi:10.4161/EPI.6.7.16263.

Irwin, R., Thursby, S., Ondičová, M., Pentieva, K., McNulty, H., Richmond, R., et al. (2019). A randomized controlled trial of folic acid intervention in pregnancy highlights a putative methylation-regulated control element at ZFP57. *Clin. Epigenetics* 11. doi:10.1186/S13148-019-0618-0.

James, P., Sajjadi, S., Tomar, A. S., Saffari, A., Fall, C. H. D., Prentice, A. M., et al. (2018). Candidate genes linking maternal nutrient exposure to offspring health via DNA methylation: a review of existing evidence in humans with specific focus on one-carbon metabolism. *Int. J. Epidemiol.* 47, 1910–1937. doi:10.1093/IJE/DYY153.

Khulan, B., Cooper, W. N., Skinner, B. M., Bauer, J., Owens, S., Prentice, A. M., et al. (2012). Periconceptional maternal micronutrient supplementation is associated with widespread gender related changes in the epigenome: A study of a unique resource in the Gambia. *Hum. Mol. Genet.* 21, 2086–2101. doi:10.1093/hmg/dds026.

Kim, D., Paggi, J. M., Park, C., Bennett, C., and Salzberg, S. L. (2019). Graph-based genome alignment and genotyping with HISAT2 and HISAT-genotype. *Nat. Biotechnol.* 37, 907–915. doi:10.1038/s41587-019-0201-4.

Kok, D. E., Dhonukshe-Rutten, R. A., Lute, C., Heil, S. G., Uitterlinden, A. G., van der Velde, N., et al. (2015). The effects of long-term daily folic acid and vitamin B 12 supplementation on genome-wide DNA methylation in elderly subjects. *Clin. Epigenetics 2015 71* 7, 1–14. doi:10.1186/S13148-015-0154-5.

Kumaran, K., Yajnik, P., Lubree, H., Joglekar, C., Bhat, D., Katre, P., et al. (2017). The Pune Rural Intervention in Young Adolescents (PRIYA) study: design and methods of a randomised controlled trial. *BMC Nutr.* 3. doi:10.1186/S40795-017-0143-5.

Lager, S., and Powell, T. L. (2012). Regulation of nutrient transport across the placenta. *J. Pregnancy* 2012. doi:10.1155/2012/179827.

Liao, Y., Smyth, G. K., and Shi, W. (2014). FeatureCounts: An efficient general purpose program for assigning sequence reads to genomic features. *Bioinformatics* 30, 923–930. doi:10.1093/bioinformatics/btt656.

Love, M. I., Huber, W., and Anders, S. (2014). Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. *Genome Biol.* 15, 550. doi:10.1186/s13059-014-0550-8.

Lucas, A., Fewtrell, M. S., and Cole, T. J. (1999). Fetal origins of adult disease: The Barker hypothesis revisited. *Curr. Opin. Endocrinol. Diabetes* Bmj 319, 245–249. doi:10.1097/01.med.0000140938.39925.4c.

MacDonald, R. S. (2000). The role of zinc in growth and cell proliferation. *J. Nutr.* 130. doi:10.1093/JN/130.5.1500S.

McCullough, L. E., Miller, E. E., Mendez, M. A., Murtha, A. P., Murphy, S. K., and Hoyo, C. (2016). Maternal B vitamins: effects on offspring weight and DNA methylation at genomically imprinted domains. *Clin. Epigenetics* 8, 1–11. doi:10.1186/S13148-016-0174-9.

McKay, J. A., Groom, A., Potter, C., Coneyworth, L. J., Ford, D., Mathers, J. C., et al. (2012). Genetic and non-genetic influences during pregnancy on infant global and site specific DNA methylation: role for folate gene variants and vitamin B12. *PLoS One* 7. doi:10.1371/JOURNAL.PONE.0033290.

Pandit, P., Galande, S., and Iris, F. (2021). Maternal malnutrition and anaemia in India: dysregulations leading to the 'thin-fat' phenotype in newborns. *J. Nutr. Sci.* 10, e91. doi:10.1017/JNS.2021.83.

Pasing, Y., Fenton, C. G., Jorde, R., and Paulssen, R. H. (2017). Changes in the human transcriptome upon vitamin D supplementation. *J. Steroid Biochem. Mol. Biol.* 173, 93–99. doi:10.1016/J.JSBMB.2017.03.016.

Pauwels, S., Ghosh, M., Duca, R., Bekaert, B., Freson, K., Huybrechts, I., et al. (2017). Dietary and supplemental maternal methyl-group donor intake and cord blood DNA methylation. *Epigenetics* 12, 1–10. doi:10.1080/15592294.2016.1257450.

Qian, Y., Huang, X., Liang, H., Zhang, Z., Xu, J., Chen, J., et al. (2016). Effects of maternal folic acid supplementation on gene methylation and being small for gestational age. *J. Hum. Nutr. Diet.* 29, 643–651. doi:10.1111/JHN.12369.

Rao, S., Kanade, A., Margetts, B. M., Yajnik, C. S., Lubree, H., Rege, S., et al. (2003). Maternal Activity in Relation to Birth Size in Rural India The Pune Maternal Nutrition Study. *Eur. J. Clin. Nutr.* 57, 531. doi:10.1038/SJ.EJCN.1601582.

Raudvere, U., Kolberg, L., Kuzmin, I., Arak, T., Adler, P., Peterson, H., et al. (2019). g:Profiler: A web server for functional enrichment analysis and conversions of gene lists (2019 update). *Nucleic Acids Res.* 47, W191–W198. doi:10.1093/nar/gkz369.

Rzepka, Z., Rok, J., Respondek, M., Pawlik, J., Beberok, A., Gryko, D., et al. (2019). Cobalamin Deficiency: Effect on Homeostasis of Cultured Human Astrocytes. *Cells* 8. doi:10.3390/CELLS8121505.

Switzeny, O. J., Müllner, E., Wagner, K. H., Brath, H., Aumüller, E., and Haslberger, A. G. (2012). Vitamin and antioxidant rich diet increases MLH1 promoter DNA methylation in DMT2 subjects. *Clin. Epigenetics 2012 41* 4, 1–11. doi:10.1186/1868-7083-4-19.

Szklarczyk, D., Gable, A. L., Lyon, D., Junge, A., Wyder, S., Huerta-Cepas, J., et al. (2019). STRING v11: protein-protein association networks with increased coverage, supporting functional discovery in genome-wide experimental datasets. *Nucleic Acids Res.* 47, D607–D613. doi:10.1093/NAR/GKY1131.

Tserga, A., Binder, A., and Michels, K. (2017). Impact of folic acid intake during pregnancy on genomic imprinting of IGF2/H19 and 1-carbon metabolism. *FASEB J.* 31, 5149–5158. doi:10.1096/FJ.201601214RR.

Umar, M., Sastry, K., and Chouchane, A. (2018). Role of Vitamin D Beyond the Skeletal Function: A Review of the Molecular and Clinical Studies. *Int. J. Mol. Sci.* 19, 1618. doi:10.3390/IJMS19061618.

Wagh, R. H., Bawdekar, R. U., Alenaini, W., Fall, C. H. D., Thomas, E. L., Bell, J. D., et al. (2020).

Maternal Micronutrient Status in Pregnancy is Associated with Child's Adiposity at 18yrs of age. in (Journal of Developmental Origins of Health and Disease). doi:10.1017/S2040174419000643.

Whitfield, M. L., George, L. K., Grant, G. D., and Perou, C. M. (2006). Common markers of proliferation. *Nat. Rev. Cancer* 6, 99–106. doi:10.1038/NRC1802.

World Health Organization (1999). Composition of a multi-micronutrient supplement to be used in pilot programmes among pregnant women in developing countries: report of a United Nations Children's Fund (UNICEF), World Health Organization (WHO) and United Nations University workshop. Available at: https://apps.who.int/iris/handle/10665/75358.

Yadav, D., Shrestha, S., Lillycrop, K., Joglekar, C., Pan, H., Holbrook, J., et al. (2018). Vitamin B 12 supplementation influences methylation of genes associated with Type 2 diabetes and its intermediate traits. *Epigenomics* 10, 71–90. doi:10.2217/EPI-2017-0102.

Yajnik, C. S., Deshpande, S. S., Jackson, A. A., Refsum, H., Rao, S., Fisher, D. J., et al. (2007). Vitamin B12 and folate concentrations during pregnancy and insulin resistance in the offspring: the Pune Maternal Nutrition Study. *Diabetologia* 51, 29–38. doi:10.1007/s00125-007-0793-y.

Yu, G., Wang, L. G., Han, Y., and He, Q. Y. (2012). clusterProfiler: an R package for comparing biological themes among gene clusters. *OMICS* 16, 284–7. doi:10.1089/omi.2011.0118.

Zeisel, S. (2017). Choline, Other Methyl-Donors and Epigenetics. *Nutrients* 9. doi:10.3390/NU9050445.

1 **Table 1**: Comparison of maternal characteristics between study participants of 3 intervention groups

	B12+MMN group : Median (IQR) (N=29, 15 boys, 14 girls)	Placebo group : Median (IQR) (N=29, 17 boys, 12 girls)	B12 alone group : Median (IQR) (N=30, 16 boys, 14 girls)	P-value (B12+ MMN Vs Placebo)	P-value (Placebo Vs B12 alone)	P-value (B12+MMN Vs B12 alone)	P-value KW (B12+MMN Vs Placebo Vs B12 alone)
Baseline							
Age (Years)	15.8 (0.9)	16.4 (0.7)	16.1 (0.9)	0.099	0.200	0.802	0.223
Hemoglobin (g/dL)	12.8 (1.8)	12.7 (2.0)	12.7 (1.5)	0.474	0.738	0.268	0.532
Vitamin B12 (pmol/L)	160.0 (87.0)	147.0 (46.0)	148.5 (63.0)	0.131	0.439	0.544	0.335
Holo-TC (pmol/L)	13.0 (8.8)	10.1 (4.3)	10.2 (8.1)	0.096	0.934	0.145	0.192
Folate (nmol/L)	15.5 (13.5)	21.7 (11.2)	17.0 (14.6)	**0.029**	0.117	0.471	0.074
Homocysteine	21.0 (11.1)	24.2 (21.8)	22.8 (10.7)	0.539	0.328	0.897	0.647
Post-intervention (Interim)							
Age (Years)	17.3 (0.8)	17.7 (0.9)	17.4 (0.8)	0.183	0.278	0.855	0.365
Hemoglobin (g/dL)	12.0 (1.6)	12.0 (1.6)	11.7 (1.2)	1.000	0.219	0.179	0.323
Vitamin B12 (pmol/L)	262.0 (122.1)	161.9 (69.0)	272.5 (165.9)	**0.000**	**0.000**	0.246	**0.000**
Holo-TC (pmol/L)	23.6 (24.1)	8.9 (5.6)	28.8 (27.7)	**0.000**	**0.000**	0.295	**0.000**
Folate (nmol/L)	19.4 (11.9)	24.9 (19.8)	23.0 (14.8)	**0.030**	0.222	0.375	0.095
Homocysteine (mmol/L)	10.0 (4.5)	24.3 (19.8)	10.6 (4.1)	**0.000**	**0.000**	0.850	**0.000**
28 weeks gestation							
Age (Years)	21.2 (2.4)	21.3 (2.0)	21.1 (1.9)	0.578	0.773	0.781	0.849
BMI (kg/m^2)	21.5 (2.5)	21.7 (3.5)	20.8 (3.7)	0.975	0.176	0.080	0.189
Hemoglobin (g/dL)	10.4 (1.7)	10.6 (1.6)	10.4 (1.9)	0.635	0.595	0.946	0.838
Vitamin B12 (pmol/L)	202.0 (121.0)	153.0 (109.0)	216.5 (180.5)	**0.015**	**0.002**	0.292	**0.003**
Holo-TC (pmol/L)	29.4 (29.8)	16.6 (14.6)	35.3 (50.2)	**0.009**	**0.005**	0.606	**0.007**
Folate (nmol/L)	42.1 (41.9)	45.6 (34.3)	48.3 (35.3)	0.497	0.850	0.655	0.786

Vitamin B2 (pmol/L)	240.0 (79.0)	226.0 (48.0)	224.0 (64.0)	0.351	0.586	0.202	0.388
Vitamin B6 (plp) (µg/ml)	4.9 (3.4)	3.6 (3.2)	3.2 (1.7)	**0.010**	0.720	**0.000**	**0.001**
Vitamin B6 (pyx) (µg/ml)	1.6 (1.2)	1.2 (0.7)	1.2 (0.5)	0.127	0.913	**0.042**	0.112
Homocysteine (µmoles/L)	6.6 (3.5)	6.6 (4.0)	6.2 (3.6)	0.339	0.252	0.952	0.469
At delivery							
Duration of intervention (months)	54.0 (38.5)	53.0 (21.5)	57.5 (27.3)	0.858	0.767	0.873	0.960
Compliance (%)	88.7 (11.7)	90.8 (13.0)	88.9 (11.4)	0.523	0.616	0.922	0.795
Vitamin B12 (pmol/L)	176.0 (80.0)	159.0 (101.0)	205.0 (90.5)	0.144	**0.033**	0.461	0.088
Holo-TC (pmol/L)	28.1 (29.5)	24.6 (22.5)	31.2 (45.6)	0.312	0.075	0.359	0.181
Folate (nmol/L)	30.1 (40.6)	43.5 (49.7)	33.6 (53.0)	0.576	0.805	0.988	0.887
Homocysteine (µmole/L)	7.8 (8.0)	8.9 (4.2)	8.6 (3.8)	0.307	0.324	0.852	0.498

Note: IQR: Inter Quartile Range, plp: pyridoxal 5-phosphate, pyx: pyridoxine ; values represent median (IQR); P-values for between group comparison calculated by Mann-Whitey test and for multi-group comparison by Kruskal Wallis test. P - Value is calculated by KRUSKAL WALLIS.

1 **Table 2**: Comparison of neonatal characteristics between study participants of 3 intervention groups

	B12+MMN group : Median (IQR) (N=29, 15 boys, 14 girls)	**Placebo group : Median (IQR) (N=29, 17 boys, 12 girls)**	**B12 alone group : Median (IQR) (N=30, 16 boys, 14 girls)**	**P-value (B12+ MMN Vs Placebo)**	**P-value (Placebo Vs B12 alone)**	**P-value (B12+MMN Vs B12 alone)**	**P-value KW (B12+MMN Vs Placebo Vs B12 alone)**
Anthropometry							
Birth weight (gms)	2951 (564)	2760 (310)	2778 (388)	0.305	0.601	0.083	0.230
Birth lengh (cm)	48.2 (2.4)	48.4 (1.8)	48.5 (1.9)	0.597	0.426	0.850	0.722
Adiposity (sum of skinfolds) (mm)	8.2 (2.4)	8.4 (2.5)	7.8 (2.5)	0.925	0.480	0.490	0.713
Cord blood biochemistry							
Vitamin B12 (pmol/L)	292.0 (226.0)	282.0 (301.0)	380.5 (442.2)	0.858	0.108	0.154	0.205
Holo-TC (pmol/L)	94.7 (94.2)	61.3 (89.2)	121.7 (71.2)	0.634	0.164	0.301	0.344
Folate (nmol/L)	47.6 (27.9)	56.9 (35.8)	55.5 (33.1)	0.413	0.671	0.562	0.666
Vitamin B2 (pmol/L)	321.0 (100.0)	289.0 (78.0)	304.0 (82.0)	0.401	0.476	0.909	0.658
Vitamin B6 (plp) (µg/ml)	32.3 (15.1)	23.4 (19.9)	23.5 (16.2)	**0.034**	0.622	0.059	0.062
Vitamin B6 (pyx) (µg/ml)	5.2 (2.6)	4.1 (1.4)	4.8 (2.7)	**0.014**	0.154	0.271	**0.044**
Homocysteine (µmol/L)	6.9 (5.0)	7.1 (5.9)	5.6 (3.4)	0.602	0.059	0.143	0.131
Cord blood hematology							
Hemoglobin (g/dL)	13.9 (1.4)	13.6 (2.2)	14.8 (1.5)	0.774	**0.038**	**0.048**	0.060
White blood cell count (*10^3/uL)	14.2 (3.5)	14.9 (6.9)	12.9 (6.7)	0.719	0.332	0.493	0.588
Granulocytes count (*10^3/uL)	7.9 (3.08)	7.6 (4.3)	7.2 (4.38)	0.949	0.324	0.455	0.597
Lymphocyte (*10^3/uL)	5.3 (2.25)	5 (2.9)	5.25 (2.02)	0.387	0.660	0.714	0.867
Monocyte	0.8 (0.68)	1 (0.45)	0.8 (0.53)	0.387	0.290	0.944	0.537

(*10^3/uL)							
Red blood cell count (*10^6/uL)	4.0 (0.6)	3.9 (0.5)	4.4 (0.6)	0.798	**0.008**	**0.036**	0.052
Platelet count (*10^3/uL)	272.5 (62.8)	270.0 (78.0)	245.0 (85.5)	0.439	0.321	0.054	0.166

Note: IQR: Inter Quartile Range, plp: pyridoxal 5-phosphate, pyx: pyridoxine ; values represent median (IQR); P-values for between group comparison calculated by Mann-Whitey test and for multi-group comparison by Kruskal Wallis test. P - Value is calculated by KRUSKAL WALLIS.

1 **Table 3**: Top 10 genes that are differentially expressed between Placebo and B12+MMN groups.

Sr. No.	Gene Symbol	Placebo vs B12+MMN (Group2 Vs Group1)		Placebo vs B12 alone (Group2 Vs Group3)		Chromosomal location
		log2FC	Adj. P-value	log2FC	Adj. P-value	
1	*KIF14*	-1.248	0.009	-0.731	1	1q32.1
2	*KNL1*	-1.203	0.009	-0.747	0.93	15q15.1
3	*KIF15*	-1.114	0.013	-0.562	1	3p21.31
4	*DEPDC1*	-1.319	0.014	-0.864	0.958	1p31.3
5	*TOP2A*	-1.085	0.014	-0.56	1	17q21.2
6	*CDCA2*	-1.206	0.016	-1.197	0.032	8p21.2
7	*ESCO2*	-1.243	0.016	-0.773	1	8p21.1
8	*SKA1*	-1.353	0.016	-0.815	1	18q21.1
9	*TPX2*	-1.073	0.016	-0.729	0.93	20q11.21
10	*TRBV7-2*	1.02	0.016	0.616	1	7q34

2

3

Figure legends

Figure 1: The Pune Maternal Nutrition Study (PMNS) and the Pune Rural Intervention in Young Adolescents (PRIYA) trial. *A) Broad plan of the study. B) CONSORT diagram of the PRIYA trial.*

Figure 2: Serial micronutrient levels in PRIYA trial. *Median concentrations of A) vitamin B12 (pmol/L), B) Holo-TC (pmol/L), C) folate (nmol/L), and D) total homocysteine (μmol/L) at baseline (17 years of age), post-intervention (18 years of age; 6-12 months after starting intervention), 28 weeks gestation and at delivery in the mothers, and in the cord blood of the baby. P-value denotes significance of difference from the placebo, using the Mann-Whitney test; MMN, multiple micronutrients.*

Figure 3: Gene enrichment analysis of genes differentially expressed between B12+MMN group and placebo. *A) Volcano plot. B) Gene enrichment analysis. C) Network analysis of 75 differentially expressed genes highlighting negative regulators of cell cycle. D) Expression plots CDCA2 in the three intervention groups (* adj P-value < 0.05); MMN, multiple micronutrients.*

Figure 4: One-Carbon Metabolism and PRIYA trial. *Micronutrient intervention provided vitamin B12 and MMN to girls from adolescent age upto delivery. In the placebo group, low vitamin B6 status could decrease the catalytic activity of Serine Hydroxy-Methyl Transferase 1 (SHMT1) resulting in a low yield of 5,10 Methylene tetrahydrofolate (MTHF) and could affect dTMP synthesis. This may cause misincorporation of uracil into the DNA. Vitamin-B6 is also a part of glycine cleavage system complex important for purine biosynthesis. Impairment of purine and pyrimidine biosynthesis may affect the cell cycle process. Other constituents of the intervention in the MMN group (vitamins B12, A, D, E, and minerals) could have additional effects on epigenetic processes, thus explaining a stronger influence on transcriptome compared to the group which received vitamin B12 alone [MMN, multiple micronutrients; B-nutrients showed in Red circles and Important enzymes of One Carbon metabolism in Black boxes].*

Figure 1

A


F0
Mother
F1
Infant
F1
Adolescent
Intervention
F1
Mother
F2
Infant
1993
1994-96
2012
2020
PMNS
N=2466
non pregnant
women
762 live births
Followed up
every 6 years
690 screened at 17 years
PRIYA trial:
557 (266 girls) randomized to
receive;
1. B12 (2µg/day) + multiple
micronutrients (MMN) OR
2. Placebo OR
3. B12 alone (2µg/day)
166
pregnancies
149 live births;
138 cord blood
samples collected;
88 cord blood
Transcriptomes
analyzed

B


Assessed for eligibility
N= 690
Excluded (n= 133)
Low Vit B12- N= 117
Anemia, n = 2
Medical disease, n = 14
Randomised
N= 557
Girls
N= 266
Boys
N= 291
Vit B12 + MMN
N= 89
Placebo
N= 86
Vit B12
N= 91
Marriages
N= 57
Marriages
N=63
Marriages
N= 62
Pregnancies
N= 50
Pregnancies
N= 59
Pregnancies
N= 57
Aborted n= 6
Aborted n= 5
Aborted n= 6
Delivered
N= 44
Delivered
N= 54
Delivered
N= 51
Transcriptomics
Analysis N= 29
Transcriptomics
Analysis N= 29
Transcriptomics
Analysis N= 30

Figure 2


A
Vitamin B12 (pmol/L)
350
300
250
200
150
***
***
***
**
*
17 Yrs
18 Yrs
28 wks
Delivery
Cord blood
Time points
B
HoloTC (pmol/L)
125
100
75
50
25
***
**
***
**
17 Yrs
18 Yrs
28 wks
Delivery
Cord blood
Time points
C
Folate (nmol/L)
50
40
30
20
*
*
17 Yrs
18 Yrs
28 wks
Delivery
Cord blood
Time points
D
Homocysteine (µmol/L)
25
20
15
10
5
***
***
17 Yrs
18 Yrs
28 wks
Delivery
Cord blood
Time points
Intervention groups
B12 +MMN
Placebo
B12 alone
* P <=0.05
** P <=0.01
*** P <=0.001

Figure 3

A



B



C



D



Figure 4


Folate (F)
NADPH + H+
DNA
dTMP
Dihydrofolate (FH2)
Thymidylate synthetase
NADPH + H+
Tetrahydrofolate (FH4)
dUMP
serine
SHMT1
Vit-B6
glycine
Formyl THF
5,10-Methylene FH4
Purine biosynthesis
MTHFR
Vit-B2
5-Methyl FH4
Methionine synthase, MSR &Vitamin B12
TCN 2
Reduced Folate carrier1 (RFC1)
Methionine
ATP
PPi +Pi
Methionine adenosyltransferase
S-Adenosylmethionine
Acceptor
Methylated acceptor
Methyl transferase
S-Adenosylhomocysteine
Adenosine
Homocysteine
Serine
CBS
Vit-B6
Cysthathionine
Cystathioase
Cysteine + NH3 + α-Ketobutyrate
IN LIVER
BHMT
Betaine
CHDH
Choline
CHK
Phosphotidylcholine